Fetuin-A Phosphorylation Status in Insulin Resistance and Metabolic Syndrome
Primary Purpose
Obesity, Metabolic Syndrome
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Weight loss
Sponsored by
About this trial
This is an interventional basic science trial for Obesity
Eligibility Criteria
Inclusion Criteria:
- 30 to 65 years of age
- obese (BMI > 30 kg⋅m2 or % fat > 30, and waist girth > 88 cm)
- weight stable over the previous 6 months
Exclusion Criteria:
- smoker
- documented cardiovascular or metabolic disease
- currently taking medication to alter lipid or glucose metabolism
- practicing regular leisure physical activity over the previous 6 months
- engaged in strenuous vocational activity over the previous 6 months
- signs or symptoms of latent heart disease
- conditions that would preclude treadmill walking
Sites / Locations
- Auburn University
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Obese individuals
Arm Description
Apparently healthy, weight-stable, obese and physically inactive male volunteers will be recruited. Intervention is an 8 to 10% weight loss induced by chronic exercise training and dietary modification
Outcomes
Primary Outcome Measures
Total plasma fetuin-A and phosphorylated fetuin-A
Measure total fetuin-A and phosphorylated fetuin-A levels in plasma
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03478046
Brief Title
Fetuin-A Phosphorylation Status in Insulin Resistance and Metabolic Syndrome
Official Title
Alterations in Phosphorylated Fetuin-A, a Novel Regulator of Insulin Action in Insulin Resistance and Metabolic Syndrome: Effects of Lifestyle Modification
Study Type
Interventional
2. Study Status
Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
October 10, 2007 (Actual)
Primary Completion Date
May 31, 2015 (Actual)
Study Completion Date
May 31, 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Auburn University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Fetuin-A has been identified as a novel physiological regulator of insulin action in vitro, in intact cells and in vivo in animals. Previous research has shown that circulating levels of fetuin-A were increased in animal models of insulin resistance and diabetes. Additionally, several human investigation studies demonstrate a correlation of fetuin-A levels with body mass index, insulin resistance, and a fatty liver. Recently, the investigators have elucidated the role of fetuin-A phosphorylation in the regulation of insulin action, demonstrating that phosphorylation is critical for the inhibitory activity of fetuin-A. The objectives of this study are twofold: (1) Quantitate phosphorylated fetuin-A levels in individuals with insulin resistance and metabolic syndrome, and (2) Investigate the effects of lifestyle modifications (acute or chronic exercise and dietary modifications) on fetuin-A phosphorylation and insulin sensitivity.
Detailed Description
There are several objectives of this study: (1) Quantitate phosphorylated fetuin-A levels and the daily variation in these levels in individuals with insulin resistance and metabolic syndrome; (2) Investigate the short-term responses of fetuin-A phosphorylation and changes in insulin resistance that occur with a single session of aerobic exercise; (3) Characterize and compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification, and; (4) Investigate the influence of weight loss on the short-term responses of fetuin-A phosphorylation and changes in insulin resistance that occur with a single session of aerobic exercise. Our hypothesis is that phosphofetuin-A levels are tightly correlated with insulin resistance and that lifestyle modifications will improve insulin sensitivity and decrease phosphorylated fetuin-A levels.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Metabolic Syndrome
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
42 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Obese individuals
Arm Type
Experimental
Arm Description
Apparently healthy, weight-stable, obese and physically inactive male volunteers will be recruited. Intervention is an 8 to 10% weight loss induced by chronic exercise training and dietary modification
Intervention Type
Other
Intervention Name(s)
Weight loss
Intervention Description
Compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification
Primary Outcome Measure Information:
Title
Total plasma fetuin-A and phosphorylated fetuin-A
Description
Measure total fetuin-A and phosphorylated fetuin-A levels in plasma
Time Frame
Total fetuin-A and phosphorylated fetuin-A levels will be measured once every 4 weeks until participant achieves a targeted weight-loss goal of 8-10%. It is anticipated that most participants will achieve their weight-loss goal within 6-10 months.
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
30 to 65 years of age
obese (BMI > 30 kg⋅m2 or % fat > 30, and waist girth > 88 cm)
weight stable over the previous 6 months
Exclusion Criteria:
smoker
documented cardiovascular or metabolic disease
currently taking medication to alter lipid or glucose metabolism
practicing regular leisure physical activity over the previous 6 months
engaged in strenuous vocational activity over the previous 6 months
signs or symptoms of latent heart disease
conditions that would preclude treadmill walking
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Suresh Mathews, PhD
Organizational Affiliation
Auburn University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Auburn University
City
Auburn
State/Province
Alabama
ZIP/Postal Code
36849
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33650781
Citation
Ren G, Bowers RL, Kim T, Mahurin AJ, Grandjean PW, Mathews ST. Serum fetuin-A and Ser312 phosphorylated fetuin-A responses and markers of insulin sensitivity after a single bout of moderate intensity exercise. Physiol Rep. 2021 Mar;9(5):e14773. doi: 10.14814/phy2.14773.
Results Reference
derived
Learn more about this trial
Fetuin-A Phosphorylation Status in Insulin Resistance and Metabolic Syndrome
We'll reach out to this number within 24 hrs